Full text is available at the source.
Abstract
The digitally immune-optimized mRNA vaccine, DVX-panH5Nx, demonstrates superior protection against H5N1 challenges compared to traditional candidate vaccine viruses (CVVs).
- DVX-panH5Nx was designed to include HA, NA, and M2 antigens from a wide range of circulating H5Nx viruses.
- The vaccine shows broad hemagglutinin neutralization and neuraminidase inhibition in both mice and ferrets.
- It is specifically optimized for N1 and N6 subtypes, which are associated with significant human health threats.
- Compared to CVVs, DVX-panH5Nx provides enhanced protection against H5N1 strains that have evolved over the past two decades.
- The findings indicate that computationally designed multivalent vaccines could effectively address challenges posed by influenza's natural variation.
Simplified